Zealand Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Zealand Pharma has a total shareholder equity of DKK8.9B and total debt of DKK281.0M, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are DKK9.6B and DKK746.7M respectively.
Key information
3.2%
Debt to equity ratio
DKK 280.99m
Debt
| Interest coverage ratio | n/a |
| Cash | DKK 8.48b |
| Equity | DKK 8.88b |
| Total liabilities | DKK 746.69m |
| Total assets | DKK 9.63b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 22Z's short term assets (DKK8.7B) exceed its short term liabilities (DKK245.6M).
Long Term Liabilities: 22Z's short term assets (DKK8.7B) exceed its long term liabilities (DKK501.1M).
Debt to Equity History and Analysis
Debt Level: 22Z has more cash than its total debt.
Reducing Debt: 22Z's debt to equity ratio has increased from 0% to 3.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 22Z has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 22Z has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.